%20--%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20100.6%2073.7'%20style='enable-background:new%200%200%20100.6%2073.7;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:%23AF001E;}%20.st1{fill:%23FFFFFF;}%20%3c/style%3e%3cg%3e%3crect%20class='st0'%20width='100.6'%20height='73.7'/%3e%3cpath%20class='st1'%20d='M25.2,36.3l-0.5,2.3c-0.2,0.7-0.2,1-0.2,1.2c0,0.5,0.2,1,0.5,1.6L31.5,53c0.5,0.9,1,1.3,2.3,1.3h5.9%20c0.8,0,1.7-0.5,0.8-1.8l-7.9-13.1c2.7-1.7,5.6-4.1,5.6-9.3c0-6.8-3.8-10.6-12.2-10.6H13.9c-1.1,0-1.4,0.4-1.4,1.5v32%20c0,1.1,0.3,1.5,1.4,1.5h5c1.1,0,1.4-0.4,1.4-1.5V26h5.2c3.3,0,4.8,1.2,4.8,4.2c0,2.8-1.2,3.6-2.5,4.2C26.3,35,25.7,34.3,25.2,36.3z%20'/%3e%3cpath%20class='st1'%20d='M45.9,48.8L45.3,53c-0.1,0.8,0.3,1.1,1,1.2c1.6,0.2,5.5,0.5,9.4,0.5c8.6,0,14.9-2.8,14.9-10.9%20c0-4.7-2.1-8.3-9.2-10.1l-4-1c-2.7-0.7-4-1.6-4-3.6c0-2.8,2.6-3.4,5.1-3.4c3.4,0,6.8,0.3,8.1,0.4c1.4,0.1,1.8-0.1,2-1.2l0.7-4.1%20c0.1-0.8-0.3-1.1-1-1.2c-1.6-0.2-5-0.5-9.4-0.5c-9,0-13.3,3.9-13.3,10.1c0,5.6,3,8.9,8.3,10.3l4,1c3.3,0.9,4.7,1.8,4.7,3.9%20c0,3-2.1,3.6-7.1,3.6c-2.3,0-6.2-0.3-7.6-0.4C46.5,47.4,46.1,47.6,45.9,48.8z'/%3e%3cpath%20class='st1'%20d='M79.4,52.9c0,1.1,0.3,1.5,1.4,1.5h5c1.1,0,1.4-0.4,1.4-1.5v-32c0-1.1-0.3-1.5-1.4-1.5h-5%20c-1.1,0-1.4,0.4-1.4,1.5V52.9z'/%3e%3c/g%3e%3c/svg%3e)
Swissmedic ha omologato il vaccino contro il Covid-19 Nuvaxovid del fabbricante Novavax per le persone a partire dai 18 anni. L'autorizzazione temporanea è la quarta in Svizzera per un prodotto immunizzatore contro il coronavirus, dopo quelle rilasciate ai farmaci di Moderna, Pfizer/BioNTech e Johnson & Johnson.
Secondo i documenti valutati dall’Istituto svizzero per gli agenti terapeutici, la protezione vaccinale è di circa il 90% sette giorni dopo la seconda dose.
Il vaccino Nuvaxovid deve essere somministrato con due dosi a distanza di tre settimane e può essere conservato in frigorifero fino a nove mesi. Si tratta di un vaccino proteico, diverso quindi nella sua concezione dai primi due citati in precedenza (che sono a mRNA) e dal terzo (a vettore virale).
Novavax non ha una filiale in Svizzera e pertanto non dispone di un’autorizzazione d’esercizio. L’azienda farmaceutica, quindi, ha fatto pervenire il 14 febbraio 2022 la domanda di omologazione tramite la società Future Health Pharma GmbH.
Il destino dei vaccini
Il Quotidiano 17.02.2022, 20:00
Entra nel canale WhatsApp RSI Info
Iscriviti per non perdere le notizie e i nostri contributi più rilevanti
https://whatsapp.com/channel/0029Vat6p4zL2ATyO8IRFJ2C
%20--%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20138.2%2048'%20style='enable-background:new%200%200%20138.2%2048;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill-rule:evenodd;clip-rule:evenodd;fill:%23AF001E;}%20.st1{fill-rule:evenodd;clip-rule:evenodd;fill:%23FFFFFF;}%20%3c/style%3e%3cpath%20class='st0'%20d='M0,48h138V0H0V48z'/%3e%3cpath%20class='st1'%20d='M9.3,31.7l-0.4,2.7C8.8,35,9,35.2,9.5,35.3c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3s-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3C11.8,12.4,9,14.9,9,19c0,3.6,2,5.8,5.4,6.7%20l2.6,0.7c2.1,0.6,3,1.2,3,2.5c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3C9.6,30.9,9.4,31,9.3,31.7'/%3e%3cpath%20class='st1'%20d='M36.4,23.6l-0.3,1.5C36,25.4,36,25.6,36,25.9c0,0.4,0.1,0.8,0.4,1.1l4.2,7.6c0.1,0.3,0.3,0.5,0.6,0.7%20c0.3,0.2,0.6,0.2,0.9,0.2h3.8c0.5,0,1.1-0.3,0.5-1.2l-5.1-8.6c1.7-1.1,3.6-2.6,3.6-6.1c0-4.4-2.5-6.9-7.9-6.9h-7.8%20c-0.7,0-0.9,0.2-0.9,1v20.8c0,0.7,0.2,1,0.9,1h3.2c0.7,0,0.9-0.2,0.9-1V16.8h3.3c2.1,0,3.1,0.8,3.1,2.8c0.1,0.6,0,1.2-0.3,1.6%20c-0.3,0.5-0.7,0.9-1.3,1.1C37.1,22.7,36.8,22.3,36.4,23.6z'/%3e%3cpath%20class='st1'%20d='M66.1,34V22.7c0-0.7-0.2-1-0.9-1h-5.8c-0.7,0-0.9,0.2-0.9,1v2.5c0,0.7,0.2,0.9,0.9,0.9h1.7v5%20c-0.6,0.1-1.1,0.1-1.7,0.1c-4.8,0-6-3.1-6-7.4c0-5.4,2-6.8,6.5-6.8c1.3,0,3.1,0.1,4.1,0.2c1,0.1,1.2,0,1.3-0.8l0.4-2.5%20c0.1-0.7,0-1-0.8-1.1c-1.8-0.2-3.6-0.3-5.4-0.2c-8.2,0-11.6,4.3-11.6,11.3s2.7,11.9,11.3,11.9c2,0.1,4,0,6-0.4%20C65.9,35.2,66.2,34.9,66.1,34'/%3e%3cpath%20class='st1'%20d='M74.9,31.7l-0.4,2.7c-0.1,0.5,0.2,0.7,0.6,0.8c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3s-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3c-5.8,0-8.6,2.6-8.6,6.6%20c0,3.6,2,5.8,5.4,6.7l2.6,0.7c2.1,0.6,3,1.2,3,2.6c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3C75.3,30.8,75,30.9,74.9,31.7'/%3e%3cpath%20class='st1'%20d='M93.1,31.7l-0.4,2.7c-0.1,0.5,0.2,0.7,0.6,0.8c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3c-0.1-0.1-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3c-5.8,0-8.6,2.6-8.6,6.6%20c0,3.6,2,5.8,5.4,6.7l2.6,0.7c2.1,0.6,3,1.2,3,2.6c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3S93.1,30.9,93.1,31.7'/%3e%3cpath%20class='st1'%20d='M120.2,23.6l-0.3,1.5c-0.1,0.3-0.1,0.5-0.1,0.8c0,0.4,0.1,0.8,0.3,1.1l4.2,7.6c0.1,0.3,0.3,0.5,0.6,0.7%20c0.3,0.2,0.6,0.2,0.9,0.2h3.8c0.5,0,1.1-0.3,0.5-1.2l-5.1-8.6c1.7-1.1,3.7-2.7,3.7-6.1c0-4.4-2.5-6.9-7.9-6.9H113%20c-0.7,0-0.9,0.2-0.9,1v20.8c0,0.7,0.2,1,0.9,1h3.2c0.7,0,0.9-0.2,0.9-1V16.8h3.3c2.1,0,3.1,0.8,3.1,2.8c0.1,0.6,0,1.2-0.3,1.6%20c-0.3,0.5-0.7,0.9-1.3,1.1C120.9,22.7,120.6,22.3,120.2,23.6'/%3e%3c/svg%3e)